Bitcoin News Update: Prenetics Secures $48M Funding, Igniting Discussion on Medical Advancements and Bitcoin Market Fluctuations

Prenetics (NASDAQ: PRE) has announced a $48 million equity raise to speed up the international growth of its IM8 health supplement line and strengthen its

treasury approach. The Hong Kong-based life sciences firm set the terms on October 27, 2025, offering 2,992,596 Class A ordinary shares (or pre-funded warrants) together with Class A and B common warrants at a price of $16.08 per unit, bringing in gross proceeds before deductions, according to . The Class A warrants have an exercise price of $24.12, representing a 50% premium, while Class B warrants are set at $32.16, a 100% premium; both are immediately exercisable and expire in five years, as detailed by StockTitan.

The capital raised will support IM8’s rapid expansion—having achieved $100 million in annual recurring revenue within just 11 months—and further Bitcoin accumulation as part of Prenetics’ combined “health-and-wealth” initiative, StockTitan noted. As of October 27, 2025, the company holds 275 Bitcoin (BTC) and intends to keep acquiring 1

per day. The transaction, scheduled to close on October 28, 2025, is being managed by Dominari Securities, a firm reportedly supported by the sons of U.S. President Donald Trump, according to .

Market response to the announcement has been varied. Shares of

dropped 15.1% in premarket trading to $14.23 on October 27, 2025, despite the stock nearly doubling over the previous quarter, as reported by Reuters. Analysts point out that the new shares and warrants could significantly dilute existing shareholders, given the company’s 14 million shares outstanding. Additional risks include dilution from warrant exercises and the unpredictability of Bitcoin’s value, which could affect Prenetics’ treasury plans, StockTitan added.

Prenetics has reiterated its focus on openness, promising that the final prospectus supplement will detail the placement agent fees and the specifics of BTC purchases. The offering is conducted under a Form F-3 shelf registration that was approved by the SEC on September 11, 2025, as mentioned in

, enabling the company to act quickly in favorable market conditions.

The company’s unique strategy—blending health product innovation with digital asset investment—has attracted attention in the consumer health industry. IM8, co-founded with David Beckham and promoted by tennis champion Aryna Sabalenka, is now recognized as the world’s fastest-growing supplement brand, according to StockTitan. At the same time, Prenetics’ Bitcoin policy sets it apart as a leader in corporate cryptocurrency adoption, though some warn about the risks of linking company value to such volatile assets.